Innovation

ExtremoChem develops small organic molecules that are obtained exclusively by chemical synthesis. These new compounds are able to stabilise proteins/enzymes and nucleic acids, either alone or in combination, against temperature stress and aggregation.

ExtremoChem compounds do not covalently bind to or form a fixed layer around the protein, so biodisponibility should not be altered. Besides stabilizing biopharmaceuticals during distribution and storage, our products can be added to the active principle at an earlier stage of their production, thus increasing the isolation yield, which is generally low due to aggregation of often expensive biomolecules and thus dramatically reducing costs.

The ExtremoChem technology is a platform for several applications, all involving protein stabilisation against heat-induced denaturation, aggregation, fibrillation and misfolding phenomena:

  1. To maintain the integrity of vaccines and other biopharmaceuticals during distribution and storage
  2. The addition of our molecules will prevent aggregation during transportation caused by shaking
  3. Our molecules can be used during the production process, where protein aggregation is a commonly observed phenomenon. This applies to the production and downstream process of some industrially and pharmaceutically interesting proteins
  4. Microarrays, imunoassays and biosensors, used in diagnostics and research, are also large and growing markets where protein stabilization is critical to ensuring accuracy and a long shelf life

 

Portugal 2020

Designação do projeto Novos estabilizadores biofármacos
Código do projeto 10785
Objetivo principal Reforçar a pesquisa, o desenvolvimento tecnológico e a inovação
Região de intervenção Lisboa
Entidade beneficiária Extremochem, Lda

 

Data de aprovação 16/05/2016
Data de início 01/01/2016
Data de conclusão 31/12/2017
Custo total elegível 330.946,08€
Apoio financeiro da União Europeia 132.378,43€
Apoio financeiro pública nacional/regional 0€

 

Objetivos Estratégicos:

  1. Introdução no Mercado de um primeiro excipinte baseado em compostos análogos aos encontrados nos organismoshipertermófilos, que possuam levada eficácia na estabilização dos principios ativos, numa gama de temperaturas alargadas de um biofármaco comercializado no Mercado, permitindo, desta forma, eliminar a necessidade de cadeia de frio.
  2. Desenvolver e comercializar compostos que permitirão estabilizar os processos de produção de biofármacos evitando a sua degradação durante as diferentes fases do processo de fabrico.
  3. Geração de receitas através da prestação de serviços e venda de compostos do catálogo .

 

Objetivos do projeto, Atividades e Resultados: